Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY MAINTENA KIT vs PENTOTHAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
Potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission; also reduces excitatory glutamate signaling.
Treatment of schizophrenia,Maintenance monotherapy for bipolar I disorder,Adjunctive treatment of major depressive disorder (off-label),Irritability associated with autistic disorder (off-label),Tourette's disorder (off-label)
Induction of general anesthesia,Induction of coma for increased intracranial pressure,Status epilepticus (off-label)
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
Induction: 3-5 mg/kg IV; Maintenance: 25-75 mg IV as needed; Rectal: 25 mg/kg (max 1.5 g) for induction.
Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing.
Terminal elimination half-life is 5-12 hours (mean 8 hours) in adults. Prolonged with hepatic impairment, obesity, or high doses due to saturation of redistribution and metabolism.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole.
Hepatic; primarily via CYP2C9 and other CYP450 enzymes.
Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites).
Hepatic metabolism (approx. 80%), renal excretion of metabolites (20-30%) and unchanged drug (0.3-1%). Biliary/fecal elimination is negligible.
Aripiprazole is >99% bound to serum albumin and alpha-1-acid glycoprotein.
Approximately 72-86% bound, primarily to albumin (with some binding to lipoproteins).
Aripiprazole: 4.9 L/kg (range 3.7-7.2 L/kg), indicating extensive tissue distribution.
Vd = 1.0-2.5 L/kg (mean 1.5 L/kg). High Vd due to extensive tissue distribution, including brain and fat; correlates with high lipid solubility.
IM (Abilify Maintena): 100% relative to oral aripiprazole after 5 monthly doses; oral: 87%.
IV: 100%. Rectal: approximately 60-80% (with variability). IM: approximately 60-70%. Oral: negligible due to extensive first-pass metabolism (not used clinically).
No adjustment for mild/moderate impairment; caution in severe impairment (Cr Cl <30 m L/min).
No specific GFR-based adjustment; use with caution in severe renal impairment due to prolonged effects.
No adjustment for mild impairment; moderate to severe (Child-Pugh class B or C): reduce dose to 300 mg/month.
Reduce dose by 50% in Child-Pugh B and C; monitor for prolonged sedation.
Not approved for pediatric use.
Induction: 5-6 mg/kg IV; Maintenance: 1-2 mg/kg IV as needed; Rectal: 25 mg/kg (max 1.5 g).
Use cautiously due to increased sensitivity; consider lower doses and monitor for adverse effects.
Reduce induction dose to 2-3 mg/kg IV; use lower maintenance doses; increased risk of hypotension and respiratory depression.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
WARNING: RESPIRATORY DEPRESSION AND APNEA; RESUSCITATIVE EQUIPMENT AND PERSONNEL MUST BE IMMEDIATELY AVAILABLE. INTRA-ARTERIAL INJECTION MAY CAUSE ARTERIAL SPASM, THROMBOSIS, AND GANGRENE.
Increased mortality in elderly dementia patients; suicidal thoughts and behaviors; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); orthostatic hypotension; leukopenia/neutropenia; seizure risk; dysphagia; body temperature dysregulation; pathological gambling and other impulse control disorders.
Respiratory depression, hypotension, laryngospasm, bronchospasm, cardiac arrhythmias, extravasation risk, and acute porphyria exacerbation.
Hypersensitivity to aripiprazole or any excipients in the formulation.
Hypersensitivity to barbiturates, acute porphyria, severe respiratory or cardiovascular instability, and inadequate airway management capability.
No specific food interactions. Grapefruit/grapefruit juice may increase aripiprazole levels (CYP3A4 inhibition). Avoid excessive alcohol consumption.
No specific food interactions. However, avoid alcohol for at least 24 hours due to additive CNS depression.
First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, including aripiprazole, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms post-delivery.
PENTOTHAL (thiopental) crosses the placenta. First trimester: limited human data, animal studies show no consistent teratogenicity. Second trimester: no specific malformation risk. Third trimester: prolonged maternal administration may cause neonatal respiratory depression, hypotonia, and withdrawal. Use only if clearly needed.
Aripiprazole is excreted in human breast milk; the estimated infant dose is 0.7–1.4% of maternal weight-adjusted dose. M/P ratio: approximately 0.3–0.5. Limited data suggest no adverse effects in breastfed infants, but long-term safety is unknown.
Thiopental is excreted in breast milk. M/P ratio is approximately 0.4–0.8. Infant dose is low (<1% of maternal weight-adjusted dose), but caution is advised due to potential CNS depression. American Academy of Pediatrics considers compatible with breastfeeding, but monitor infant for sedation.
No specific dose adjustment recommended based on pharmacokinetic changes; however, therapeutic drug monitoring may be considered due to altered metabolism in pregnancy. The long-acting injectable formulation (Abilify Maintena) requires careful timing of doses postpartum to avoid relapse.
Pregnancy may increase volume of distribution and clearance, but dosing adjustments for thiopental are not routinely recommended. Use lowest effective dose due to increased sensitivity to barbiturates. For cesarean section, standard induction doses (3-5 mg/kg IV) are used; reduced doses may be needed if combined with other sedatives.
Administer every 4 weeks by intramuscular injection only. Do not substitute for oral aripiprazole on a mg-per-mg basis due to different pharmacokinetics. Requires initiation and continuation with oral aripiprazole for 14 days to establish tolerability. Monitor for neuroleptic malignant syndrome, tardive dyskinesia, and metabolic changes. Dose adjustments needed in patients with known CYP2D6 poor metabolizer status or concurrent use of strong CYP2D6 or CYP3A4 inhibitors.
Pentothal (thiopental) is an ultra-short-acting barbiturate used for induction of anesthesia. It causes dose-dependent respiratory depression and hypotension. Administer only in a controlled setting with resuscitation equipment. Note that it is highly alkaline (p H 10-11) and extravasation causes severe tissue necrosis. Also, it is contraindicated in porphyria.
This medication is given as an injection every 4 weeks by a healthcare professional.,Do not stop taking your oral aripiprazole until your doctor tells you to.,Seek emergency care if you experience fever, muscle stiffness, confusion, or irregular heartbeat.,Avoid alcohol and driving until you know how this medicine affects you.,Report any uncontrolled movements of the face, tongue, or other body parts to your doctor.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
You will receive this medication only under the supervision of an anesthesiologist.,It will cause you to fall asleep quickly and you may feel drowsy for several hours after the procedure.,Do not drive or operate machinery for at least 24 hours after receiving this medication.,Inform your doctor if you have a history of porphyria, liver disease, or allergies to barbiturates.,You may experience a bad taste or cough upon injection.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY MAINTENA KIT vs PENTOTHAL, answered by our medical review team.
ABILIFY MAINTENA KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.. PENTOTHAL is a Barbiturate Anesthetic that works by Potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission; also reduces excitatory glutamate signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY MAINTENA KIT and PENTOTHAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY MAINTENA KIT is: 400 mg IM once monthly after establishing tolerability with oral aripiprazole.. The standard adult dose of PENTOTHAL is: Induction: 3-5 mg/kg IV; Maintenance: 25-75 mg IV as needed; Rectal: 25 mg/kg (max 1.5 g) for induction.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY MAINTENA KIT and PENTOTHAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY MAINTENA KIT is classified as Category C. First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, includin. PENTOTHAL is classified as Category C. PENTOTHAL (thiopental) crosses the placenta. First trimester: limited human data, animal studies show no consistent teratogenicity. Second trimester: no specific malformation risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.